Business news – Page 93
-
Business
Does chemical regulation boost innovation?
Report suggests that supply of innovation responds to extra demand created by new laws
-
Business
Talk of a $6.6bn deal for Elan
Potential offer from Royalty Pharma comes as Elan ponders how to spend its cash from Tysabri rights
-
Business
$595m octreotide deal grabs Roche
Company will get worldwide rights to oral formulation of growth hormone drug
-
Business
Merck resolves Vytorin case for $688m
Investors say the company knew about Enhance trial failure but withheld information
-
Business
BMS sells OTC drugs for $482m
Bristol-Myers Squibb will offload rights to a range of over-the-counter products to Reckitt Benckiser
-
Business
Biogen buys Tysabri from Elan for $3.25bn
Elan earns huge cash injection for blockbuster drug
-
Business
GSK commits to AllTrials data disclosure
Company will begin publishing all clinical study reports
-
Business
Reach reviewed: no change required
But disproportionate cost of compliance for small and medium size companies should be reduced, European commission says
-
Business
EU proposes neonicotinoid pesticide ban
Clothianidin, thiamethoxam and imidacloprid at centre of debate over declining bee populations
-
Business
Zoetis IPO launches at $2.2bn
Pfizer spin off will be a big player among a relatively small number of public companies focusing on animal heatlh
-
Business
DCD in New Zealand milk
Dicyandiamide poses no food risk but fertiliser companies have suspended sales
-
Business
Unrest over US gas exports
Dow says exports will increase cost of gas and decrease price stability
-
Business
Sabic invests $500m in new R&D centres
Four centres to be created: two in Saudi Arabia, one in India and one in China
-
Opinion
Name reactions: how does the label stick?
Derek Lowe investigates the long running tradition of naming reactions after their inventors
-
Business
Allergan buys MAP for $958m
Deal strengthens Allergan’s position in neurology with Levadex for treating migraine
-
Business
OM Group to exit cobalt business
Deal worth up to $435 million includes downstream activities, in particular cobalt refining in Kokkola, Finland
-
Business
Vasella to leave Novartis in August
Long serving chair of the board of directors will be succeeded by Jörg Reinhardt
-
Business
Flu vaccine without the eggs approved
Flublok does not require flu virus or eggs for manufacture